Canada’s Lung Cancer Therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of X.X% during the forecast period.
Canada’s lung cancer therapeutics market is expected to grow significantly over the forecast period. In Canada, Lung cancer is the leading cause of cancer deaths for both males (25.2% of cancer deaths) and females (26.1% of cancer deaths). In Canada, lung cancer accounts for 13% of all new cancer cases & 25% of deaths due to cancer. and It is estimated that nearly 29,300 Canadians will develop lung cancer in 2019 and 21,000 will die from it. The incidence of lung cancer remains higher in males (66.0 per 100,000) than females (59.6 per 100,000). Smoking is thought of as the main cause of lung cancer, though lung cancer also follows in non-smokers.
Market Driving Factors
The driving factors for the growth of the Lung Cancer Therapeutics market in Canada include rising prevalence, increasing patient alertness, persistent investment in R&D, and greater adoption of sophisticated and advanced therapies. Growth in the lung cancer therapeutics market can also be attributed to patient’s constant contact with radiation and carcinogens. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment. Increasing adoption and demand for targeted therapies, which is considered to be the foundation of precision medicine is one of the most prominent driving factors for the growth of Canada’s Lung Cancer Therapeutics Market.